K. Mrózek

C. Bloomfield, R. Larson, K. Mrózek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007, Blood.

Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome.

K. Mrózek, J. Lubiński, J. Limon, 1995, Cancer genetics and cytogenetics.

Recurrent chromosome changes in two adult fibrosarcomas

K. Mrózek, M. Debiec‐Rychter, J. Limon, 1998, Genes, chromosomes & cancer.

Controlled variable selection in Weibull mixture cure models for high‐dimensional data

J. Byrd, K. Mrózek, K. Archer, 2022, Statistics in medicine.

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Gregory L. Wheeler, E. Mardis, J. Byrd, 2022, Blood advances.

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

C. Bloomfield, J. Byrd, K. Mrózek, 2019, Leukemia.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

Accumulation of chromosomal changes in human glioma progression. A cytogenetic study of 50 cases.

K. Mrózek, P. Liberski, M. Debiec‐Rychter, 1995, Cancer genetics and cytogenetics.

Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005 .

Cytogenetic findings in two synovial sarcomas.

K. Mrózek, J. Limon, J. Jaśkiewicz, 1989, Cancer genetics and cytogenetics.

Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literature.

C. Bloomfield, K. Mrózek, N. Mandahl, 1998, Gynecologic oncology.

On the significance of trisomy 7 and sex chromosome loss in renal cell carcinoma.

F. Mitelman, K. Mrózek, N. Mandahl, 1990, Cancer genetics and cytogenetics.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Heather L. Mulder, Erin K. Hedlund, Michael C. Rusch, 2014, The New England journal of medicine.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

C. Bloomfield, K. Mrózek, M. Perales, 2020, International journal of laboratory hematology.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2014, The Journal of clinical investigation.

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

L. Campbell, R. Larson, K. Mrózek, 2022, Blood advances.

Translocation t(12;22)(q13;q12.2–12.3) in a clear cell sarcoma of tendons and aponeuroses

C. Bloomfield, K. Mrózek, C. Karakousis, 1993, Genes, chromosomes & cancer.

Leukemia Group B study myeloid leukemia and MLL partial tandem duplication: a Cancer and Long-term disease-free survivors with cytogenetically normal acute

M. Caligiuri, P. Paschka, R. Larson, 2013 .

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetics in Acute Leukemia

C. Bloomfield, K. Mrózek, N. Heerema, 2022 .

Trisomy of chromosome 12 in a case of thecoma of the ovary.

K. Mrózek, J. Limon, B. Nedoszytko, 1990, Gynecologic oncology.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

C. Bloomfield, J. Byrd, R. Larson, 2002, Blood.

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2006, Blood.

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Cancer research.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

C. Bloomfield, P. Paschka, K. Mrózek, 2007, Blood.

X-linked anhidrotic ectodermal dysplasia and de novo t(X;1) in a female

K. Mrózek, J. Limon, M. Castrén, 1991, Human Genetics.

Cytogenetics and molecular genetics of acute lymphoblastic leukemia.

K. Mrózek, P. Aplan, David P. Harper, 2009, Hematology/oncology clinics of North America.

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia

M. Caligiuri, C. Bloomfield, C. Plass, 2001, Proceedings of the National Academy of Sciences of the United States of America.

The prognostic and functional role of microRNAs in acute myeloid leukemia.

Guido Marcucci, C. Bloomfield, M. Radmacher, 2011, Blood.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Christian Langer, Guido Marcucci, M. Caligiuri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

C. Bloomfield, M. Ross, M. Radmacher, 2008, Blood.

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

C. Bloomfield, K. Mrózek, S. Bigner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

Guido Marcucci, C. Bloomfield, K. Mrózek, 2005, Current opinion in hematology.

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Sandya Liyanarachchi, Herbert Auer, Ramana V Davuluri, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.

C. Bloomfield, K. Mrózek, K. Heinonen, 2000, International journal of hematology.

Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells

C. Bloomfield, S. Volinia, R. Garzon, 2019, Leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Guido Marcucci, Stefano Volinia, Andrew J. Carroll, 2014, Proceedings of the National Academy of Sciences.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Guido Marcucci, Stefano Volinia, Jessica Kohlschmidt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COLIA1-PDGFB gene fusion in dermatofibrosarcoma protuberans. molecular analysis of a case with an unusual large marker containing sequences from chromosomes 7, 8, 17, 21, and 22.

K. Mrózek, J. Limon, F. Pedeutour, 2002, Cancer genetics and cytogenetics.

Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality

C. Bloomfield, K. Mrózek, A. Niezabitowski, 2001, Genes, chromosomes & cancer.

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

J. Byrd, R. Garzon, K. Mrózek, 2021, Blood advances.

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

C. Bloomfield, J. Byrd, K. Mrózek, 2016, Haematologica.

Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance

C. Bloomfield, K. Mrózek, 2015 .

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.

Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia

K. Mrózek, N. Heerema, V. Coppola, 2021, Nature Communications.

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

C. Bloomfield, P. Paschka, K. Mrózek, 2008, Current opinion in oncology.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of telomeric associations and chromatid exchanges and breaks in human ovarian carcinoma.

K. Mrózek, J. Limon, 2008, Hereditas.

Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B

C. Bloomfield, R. Larson, K. Mrózek, 2004, British journal of haematology.

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.

C. Bloomfield, R. Larson, M. L. Le Beau, 1999, Blood.

Evidence for Phenotypic Plasticity in Aggressive Triple-Negative Breast Cancer: Human Biology Is Recapitulated by a Novel Model System

R. Cardiff, J. Delrow, K. Mrózek, 2012, PloS one.

Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry

C. Bloomfield, C. Schiffer, K. Mrózek, 1998, Leukemia.

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.

C. Bloomfield, F. Speleman, J. Vandesompele, 2004, Blood.

Cytogenetics of Synovial Sarcoma: Presentation of Ten New Cases and Review of the Literature

F. Mitelman, K. Mrózek, A. Rydholm, 1991, Genes, chromosomes & cancer.

Clinical importance of cytogenetics in acute myeloid leukaemia.

C. Bloomfield, K. Mrózek, K. Heinonen, 2001, Best practice & research. Clinical haematology.

CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5

K. Mrózek, V. Seewaldt, G. Bean, 2005, Journal of Cell Science.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Guido Marcucci, Marco Marra, Zhaohui Gu, 2016, Nature Communications.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

Heather L. Mulder, Michael C. Rusch, Michael N. Edmonson, 2016, Nature Genetics.

Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review

C. Bloomfield, K. Mrózek, G. Marcucci, 2007, British journal of haematology.

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ML‐1 cell line lacks a germline MLL locus

T. Shows, K. Mrózek, S. Sait, 1996, Genes, chromosomes & cancer.

Trisomy 12 and 4 in a thecoma of the ovary.

K. Mrózek, J. Limon, J. Emerich, 1992, Gynecologic oncology.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions

M. Caligiuri, C. Bloomfield, K. Mrózek, 2006, Clinical Cancer Research.

Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line.

M. Caligiuri, C. Bloomfield, C. Plass, 2002, Blood.

MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.

C. Bloomfield, M. Radmacher, C. Croce, 2009, Best practice & research. Clinical haematology.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, R. Garzon, 2021, Blood advances.

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

C. Bloomfield, R. Larson, K. Mrózek, 2020, Blood advances.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

C. Bloomfield, R. Kittles, P. Paschka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007 .

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.

M. Loh, C. Bloomfield, M. Relling, 2014, Blood.

Acquired copy number alterations in adult acute myeloid leukemia genomes

J. Kitzman, R. Wilson, R. Fulton, 2009, Proceedings of the National Academy of Sciences.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Yi Ning, Kellie J Archer, C. Bloomfield, 2006, Blood.

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia

C. Bloomfield, J. Byrd, R. Garzon, 2019, Haematologica.

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

C. Bloomfield, J. Byrd, R. Vij, 2021, Blood advances.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.

C. Bloomfield, K. Mrózek, 2008, Journal of the National Cancer Institute. Monographs.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Leukemia.

myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic

M. Ross, M. Radmacher, P. Paschka, 2013 .

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 1998, Cancer research.

Absence of structural rearrangements of chromosome 11 in human primary malignant melanoma.

K. Mrózek, J. Limon, B. Nedoszytko, 1992, Cancer genetics and cytogenetics.

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, Blood.

Clear cell sarcoma of tendons and aponeuroses with t(12;22) (q13;q12) diagnosed initially as malignant melanoma.

K. Mrózek, J. Limon, B. Nedoszytko, 1996, Cancer genetics and cytogenetics.

The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia.

M. Caligiuri, C. Bloomfield, N. Zeleznik-Le, 2001, Cancer research.

Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia.

C. Bloomfield, K. Mrózek, 2006, Hematology. American Society of Hematology. Education Program.

Molecular cytogenetic characterization of the KG‐1 and KG‐1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization

C. Bloomfield, K. Mrózek, S. M. Tanner, 2003, Genes, chromosomes & cancer.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop †

C. Bloomfield, S. Raimondi, K. Mrózek, 2002, Genes, chromosomes & cancer.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances

C. Bloomfield, H. Döhner, K. Mrózek, 2007, Current opinion in hematology.

Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 1998, British journal of haematology.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

C. Bloomfield, J. Byrd, K. Metzeler, 2018, Blood advances.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

C. Bloomfield, R. Larson, K. Mrózek, 2019, Leukemia.

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Proceedings of the National Academy of Sciences.

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2002, International journal of oncology.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

C. Bloomfield, K. Mrózek, R. Mayer, 1997, Blood.

Der(16)t(1;16) is a secondary chromosome aberration in at least eighteen different types of human cancer

C. Bloomfield, K. Mrózek, 1998, Genes, chromosomes & cancer.

Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia.

K. Mrózek, D. Grimwade, 2011, Hematology/oncology clinics of North America.

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

C. Bloomfield, P. Paschka, R. Larson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Stefano Volinia, Jessica Kohlschmidt, Karl Kroll, 2017, Cancer research.

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

C. Bloomfield, W. Hiddemann, H. Döhner, 2014, Haematologica.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

C. Bloomfield, L. Garraway, Judit Jané-Valbuena, 2018, Blood advances.

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

C. Bloomfield, J. Byrd, R. Garzon, 2020 .

Acute myeloid leukemia with adverse cytogenetic risk.

C. Bloomfield, K. Mrózek, 2012, Oncology.

Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Ashley D. Hill, M. Loh, J. Downing, 2019, Nature Genetics.

Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

R. Larson, K. Mrózek, M. Liedtke, 2022, Blood advances.

Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

K. Mrózek, Krzysztof Mrózek, 2008, Seminars in oncology.

Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix–induced apoptosis

K. Mrózek, Katherine B. Hobbs, V. Seewaldt, 2001, The Journal of cell biology.

Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis.

K. Mrózek, V. Seewaldt, E. Dietze, 2001, Cancer research.

Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study.

C. Bloomfield, R. Kittles, P. Paschka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA expression in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Mrózek, 2009, Current hematologic malignancy reports.

patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction

C. Bloomfield, J. Byrd, R. Larson, 2002 .

Molecular signatures in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Mrózek, 2009, Current opinion in hematology.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Annals of hematology.

High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults

C. Bloomfield, Cheng Cheng, J. Radich, 2015 .

Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q

C. Bloomfield, K. Mrózek, K. Heinonen, 2002, Genes, chromosomes & cancer.

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2011 .

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2008, International journal of oncology.

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

K. Mrózek, W. Stock, A. Carroll, 2023, Leukemia.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .

Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461

C. Bloomfield, R. Larson, K. Mrózek, 2004 .

Molecular cytogenetics in acute myeloid leukemia in adult patients: practical implications.

K. Mrózek, 2022, Polish archives of internal medicine.

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

myeloid malignancies amplification and support an etiologic role for MLL gain of function in Expression analyses identify MLL as a prominent target of 11q23

J. Vandesompele, A. Hagemeijer, K. Mrózek, 2013 .

Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour

C. Bloomfield, K. Mrózek, P. Nagesh Rao, 1996, British journal of haematology.

Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

C. Bloomfield, C. Croce, R. Garzon, 2018, Blood.

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, K. Metzeler, 2021, Haematologica.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Cytogenetics of Acute Leukemia

C. Bloomfield, S. Raimondi, K. Mrózek, 2013 .

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Jesse J. Plascak, R. Larson, K. Mrózek, 2023, Blood advances.

Clinical significance of cytogenetics in acute myeloid leukemia.

C. Bloomfield, A. de la Chapelle, K. Mrózek, 1997, Seminars in oncology.

Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Leukemia.

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.

M. Caligiuri, C. Bloomfield, C. Croce, 1996, Cancer research.

A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification

C. Bloomfield, J. Byrd, R. Garzon, 2018, Blood.

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

C. Bloomfield, C. Schiffer, R. Larson, 2001, Blood.

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

K. Mrózek, S. Baker, W. Stock, 2023, Blood advances.

Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas.

K. Mrózek, J. Lubiński, J. Limon, 2005, Oncology reports.

Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, M. Radmacher, P. Paschka, 2007 .

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

C. Bloomfield, P. Paschka, K. Mrózek, 2008, Current opinion in oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

Karl W. Kroll, C. Bloomfield, J. Byrd, 2016, Leukemia.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Cancer research.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells

C. Bloomfield, S. Volinia, R. Garzon, 2019, Leukemia.

Discovery of clinically relevant fusions in pediatric cancer

R. Wilson, E. Mardis, D. Koboldt, 2021, BMC Genomics.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

M. Caligiuri, C. Bloomfield, J. Byrd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).

C. Bloomfield, M. Radmacher, R. Larson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations.

M. Caligiuri, C. Bloomfield, C. Croce, 1994, Cancer research.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

C. Bloomfield, J. Byrd, S. Volinia, 2016, Leukemia.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2006, Blood.

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.

C. Bloomfield, M. Relling, C. Pui, 2014, Blood.

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

R M Stone, S L George, M. Caligiuri, 2011, Leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.